Blood Sugar News and Research

RSS

Blood sugar concentration, or glucose level, refers to the amount of glucose present in the blood of a human or animal. Normally, in mammals the blood glucose level is maintained at a reference range between about 3.6 and 5.8 mM (mmol/l). It is tightly regulated as a part of metabolic homeostasis.

Fructose may not be as bad for us as previously thought

A new study by researchers at St. Michael's Hospital suggests that fructose may not be as bad for us as previously thought and that it may even provide some benefit.

22 Jun 2012

Bariatric surgery can remit or prevent diabetic nephropathy in obese patients

In many obese diabetic patients, one of the most dreaded complications of Type 2 diabetes can be put into remission or prevented entirely with bariatric surgery, according to a new study from the Cleveland Clinic presented here at the 29th Annual Meeting of the American Society for Metabolic & Bariatric Surgery.

21 Jun 2012

Bariatric surgery improves kidney function in severely obese patients with CKD

Severely obese patients with chronic kidney disease (CKD) saw significant improvements in kidney function within one year of bariatric surgery, according to a new study presented here at the 29th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).

20 Jun 2012

Skin disease shares common inflammatory pathway with metabolic disorder

Psoriasis is an independent risk for Type 2 Diabetes, according to a new study by researchers with the Perelman School of Medicine at the University of Pennsylvania, with the greatest risk seen in patients with severe psoriasis.

19 Jun 2012

Simple, inexpensive method for preventing type 2 diabetes

A simple, inexpensive method for preventing type 2 diabetes that relies on calling people and educating them on the sort of lifestyle changes they could make to avoid developing the disease has proven effective in a study conducted by researchers at the University of California, San Francisco (UCSF) and the City of Berkeley Department of Public Health.

16 Jun 2012

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer.

15 Jun 2012

Rising blood sugar points to developing stroke risk

People with prediabetes have a somewhat increased risk for stroke, say the authors of a meta-analysis.

13 Jun 2012

Short-term intensive weight management program effective alternative to bariatric surgery

A study by a team of clinicians and researchers at the Joslin Diabetes Center in Boston has shown for the first time that patients with diabetes who enrolled in a short-term intensive weight management program were able to lose weight and keep it off on their own for four years.

13 Jun 2012

Controlled blood sugar in diabetes can prevent painful nerves: but at what cost?

Aggressive control of blood sugar levels in diabetes can help to prevent a painful condition affecting patients’ nerves, according to a new systematic review in The Cochrane Library. However, the review suggests that optimal target levels need to be established to prevent serious complications.

13 Jun 2012

Liquid glucagon formulation may be useable in standard diabetes pumps

JDRF-funded researchers at Oregon Health & Science University (OHSU) and Legacy Health have discovered a liquid glucagon formulation that may be useable in standard diabetes pumps.

13 Jun 2012

New tool should serve as cellular equivalent for children with CDG syndromes

Just as Gotham City uses the Bat Signal to call for Batman's aid, a new tool developed by scientists from the Sanford-Burnham Medical Research Institute in La Jolla, California, should serve as the cellular equivalent for children with glycosylation disorders, sometimes called "CDG syndromes."

13 Jun 2012

Long-term insulin use does not increase risk of heart disease in people with diabetes

Researchers at McMaster University have discovered that long-term insulin use does not harm people with diabetes or pre-diabetes or put them at risk of heart attacks, strokes or cancer.

13 Jun 2012

Almased helps patients with type 2 diabetes lose weight, gain better sugar control

A pilot study shows that a protein-rich meal replacement made from soy, yogurt, and honey (Almased) helps patients with type 2 diabetes lose weight, gain better control of their blood sugar, and decrease their daily insulin dose. Patients in the study also lowered their body mass index (BMI), waist and hip circumference, and fasting glucose levels, while improving their HDL-cholesterol and triglycerides.

12 Jun 2012

Ampio’s CRO completes Optina clinical trial for DME

Ampio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, whose lead drugs treat inflammatory diseases, including osteoarthritis and complications of Diabetes Mellitus such as diabetic macular edema (and others) announced today that it's CRO has completed analysis of the primary end point in the Optina clinical trial for DME conducted at St Michael Diabetes Hospital in Toronto Canada.

11 Jun 2012

Data from first feasibility study of artificial pancreas system

Results from the first feasibility study of an advanced first-generation artificial pancreas system were presented today at the 72nd Annual American Diabetes Association Meeting in Philadelphia. Findings from the study indicated that the Hypoglycemia-Hyperglycemia Minimizer (HHM) System was able to automatically predict a rise and fall in blood glucose and correspondingly increase and/or decrease insulin delivery safely.

11 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Researchers identify new mitochondrial protein complex linked with type 2 diabetes

Researchers at Metabolic Solutions Development Company, LLC (MSDC) have identified a mitochondrial protein complex through which anti-diabetic drugs exert their insulin sensitizing effects when used to treat patients diagnosed with type 2 diabetes.

11 Jun 2012

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin.

11 Jun 2012

Amylin announces results from SYMLIN clinical studies on type 2 or 1 diabetes

Amylin Pharmaceuticals, Inc. today announced results from new analyses of previously completed clinical studies demonstrating that patients with type 2 or type 1 diabetes achieved a greater proportion of blood glucose measurements in the normal range when SYMLIN (pramlintide acetate) injection treatment was used along with insulin.

11 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012